Drug-associated thrombotic microangiopathies

Seminars in Thrombosis and Hemostasis

Volumn 38, Issue 8, 2012, Pages 839-844

  Kreuter, Justin ^a   Winters, Jeffrey L ^a  

^a MAYO CLINIC   (United States)

Author keywords

drug; plasma exchange; thrombotic microangiopathy

Indexed keywords

CLOPIDOGREL; CYCLOSPORIN; GEMCITABINE; MITOMYCIN C; PRASUGREL; QUININE; TACROLIMUS; TICLOPIDINE; VASCULOTROPIN INHIBITOR;

ARTICLE; HUMAN; PLASMAPHERESIS; PRIORITY JOURNAL; THROMBOTIC THROMBOCYTOPENIC PURPURA;

HUMANS; PHARMACEUTICAL PREPARATIONS; THROMBOTIC MICROANGIOPATHIES;

EID: 84868528508     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0032-1328886     Document Type: Article

References (53)

1. Moake J. L. Thrombotic microangiopathies. N Engl J Med: 2002; 347 8 589 600
2. Copelovitch L., Kaplan B. S. The thrombotic microangiopathies. Pediatr Nephrol: 2008; 23 10 1761 1767
3. Szczepiorkowski Z. M., Winters J. L., Bandarenko N., et al. Guidelines on the use of therapeutic apheresis in clinical practiceevidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher: 2010; 25 3 83 177
4. Bennett C. L., Davidson C. J., Raisch D. W., Weinberg P. D., Bennett R. H., Feldman M. D. Thrombotic thrombocytopenic purpura associated with ticlopidine in the setting of coronary artery stents and stroke prevention. Arch Intern Med: 1999; 159 21 2524 2528
5. Bennett C. L., Kiss J. E., Weinberg P. D., et al. Thrombotic thrombocytopenic purpura after stenting and ticlopidine. Lancet: 1998; 352 9133 1036 1037 (Pubitemid 28438583)
6. Steinhubl S. R., Tan W. A., Foody J. M., Topol E. J. Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. EPISTENT investigators. Evaluation of platelet IIb/IIIa inhibitor for stenting. JAMA: 1999; 281 9 806 810 (Pubitemid 29113740)
7. Zakarija A., Kwaan H. C., Moake J. L., et al. Ticlopidine- and clopidogrel-associated thrombotic thrombocytopenic purpura (TTP): review of clinical, laboratory, epidemiological, and pharmacovigilance findings (1989-2008). Kidney Int Suppl: 2009; 112 S20 S24
8. Bennett C. L., Weinberg P. D., Rozenberg-Ben-Dror K., Yarnold P. R., Kwaan H. C., Green D. Thrombotic thrombocytopenic purpura associated with ticlopidine. A review of 60 cases. Ann Intern Med: 1998; 128 7 541 544 (Pubitemid 28177661)
9. Tsai H. M., Rice L., Sarode R., Chow T. W., Moake J. L. Antibody inhibitors to von Willebrand factor metalloproteinase and increased binding of von Willebrand factor to platelets in ticlopidine-associated thrombotic thrombocytopenic purpura. Ann Intern Med: 2000; 132 10 794 799 (Pubitemid 30317794)
10. Mauro M., Zlatopolskiy A., Raife T. J., Laurence J. Thienopyridine-linked thrombotic microangiopathy: association with endothelial cell apoptosis and activation of MAP kinase signalling cascades. Br J Haematol: 2004; 124 2 200 210 (Pubitemid 38122193)
11. Symeonidis A., Kouraklis-Symeonidis A., Seimeni U., et al. Ticlopidine-induced aplastic anemia: two new case reports, review, and meta-analysis of 55 additional cases. Am J Hematol: 2002; 71 1 24 32 (Pubitemid 34988582)
12. Bennett C. L., Connors J. M., Carwile J. M., et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med: 2000; 342 24 1773 1777 (Pubitemid 30390236)
13. Bennett C. L., Kim B., Zakarija A., et al. Two mechanistic pathways for thienopyridine-associated thrombotic thrombocytopenic purpura: a report from the SERF-TTP Research Group and the RADAR Project. J Am Coll Cardiol: 2007; 50 12 1138 1143 (Pubitemid 47381493)
14. Qureshi Z. P., Armstrong J., Bennett C. L. Ticlopidine-, clopidogrel-, and prasugrel-associated thrombotic purpura: a twenty year review. Blood: 2011; 118 21 969
15. Zarifian A., Meleg-Smith S., O'donovan R., Tesi R. J., Batuman V. Cyclosporine-associated thrombotic microangiopathy in renal allografts. Kidney Int: 1999; 55 6 2457 2466 (Pubitemid 29256501)
16. Van Buren D., Van Buren C. T., Flechner S. M., Maddox A. M., Verani R., Kahan B. D. De novo hemolytic uremic syndrome in renal transplant recipients immunosuppressed with cyclosporine. Surgery: 1985; 98 1 54 62 (Pubitemid 16136519)
17. Young B. A., Marsh C. L., Alpers C. E., Davis C. L. Cyclosporine- associated thrombotic microangiopathy/hemolytic uremic syndrome following kidney and kidney-pancreas transplantation. Am J Kidney Dis: 1996; 28 4 561 571 (Pubitemid 26337596)
18. Trimarchi H. M., Truong L. D., Brennan S., Gonzalez J. M., Suki W. N. FK506-associated thrombotic microangiopathy: report of two cases and review of the literature. Transplantation: 1999; 67 4 539 544 (Pubitemid 29114215)
19. Elliott M. A., Nichols W. L. Jr, Plumhoff E. A., et al. Posttransplantation thrombotic thrombocytopenic purpura: a single-center experience and a contemporary review. Mayo Clinic Proceedings: 2003; 78 4 421 430 (Pubitemid 36373943)
20. Perico N., Zoja C., Benigni A., Ghilardi F., Gualandris L., Remuzzi G. Effect of short-term cyclosporine administration in rats on renin-angiotensin and thromboxane A2: possible relevance to the reduction in glomerular filtration rate. J Pharmacol Exp Ther: 1986; 239 1 229 235 (Pubitemid 16006361)
21. McCauley J., Bronsther O., Fung J., Todo S., Starzl T. E. Treatment of cyclosporin-induced haemolytic uraemic syndrome with FK506. Lancet: 1989; 2 8678-8679 1516 (Pubitemid 20018156)
22. Myers J. N., Shabshab S. F., Burton N. A., Nathan S. D. Successful use of cyclosporine in a lung transplant recipient with tacrolimus-associated hemolytic uremic syndrome. J Heart Lung Transplant: 1999; 18 10 1024 1026 (Pubitemid 29505492)
23. Wiener Y., Nakhleh R. E., Lee M. W., et al. Prognostic factors and early resumption of cyclosporin A in renal allograft recipients with thrombotic microangiopathy and hemolytic uremic syndrome. Clin Transplant: 1997; 11 3 157 162 (Pubitemid 27230790)
24. Zent R., Katz A., Quaggin S., et al. Thrombotic microangiopathy in renal transplant recipients treated with cyclosporin A. Clin Nephrol: 1997; 47 3 181 186 (Pubitemid 27119711)
25. Fung M. C., Storniolo A. M., Nguyen B., Arning M., Brookfield W., Vigil J. A review of hemolytic uremic syndrome in patients treated with gemcitabine therapy. Cancer: 1999; 85 9 2023 2032 (Pubitemid 29202779)
26. Humphreys B. D., Sharman J. P., Henderson J. M., et al. Gemcitabine-associated thrombotic microangiopathy. Cancer: 2004; 100 12 2664 2670 (Pubitemid 38715773)
27. Gore E. M., Jones B. S., Marques M. B. Is therapeutic plasma exchange indicated for patients with gemcitabine-induced hemolytic uremic syndrome? J Clin Apher: 2009; 24 5 209 214
28. Glezerman I., Kris M. G., Miller V., Seshan S., Flombaum C. D. Gemcitabine nephrotoxicity and hemolytic uremic syndrome: report of 29 cases from a single institution. Clin Nephrol: 2009; 71 2 130 139
29. Lesesne J. B., Rothschild N., Erickson B., et al. Cancer-associated hemolytic-uremic syndrome: analysis of 85 cases from a national registry. J Clin Oncol: 1989; 7 6 781 789 (Pubitemid 19145601)
30. Proia A. D., Harden E. A., Silberman H. R. Mitomycin-induced hemolytic-uremic syndrome. Arch Pathol Lab Med: 1984; 108 12 959 962 (Pubitemid 15189163)
31. Bradner W. T. Mitomycin C: a clinical update. Cancer Treat Rev: 2001; 27 1 35 50 (Pubitemid 32229684)
32. Cattell V. Mitomycin-induced hemolytic uremic kidney. An experimental model in the rat. Am J Pathol: 1985; 121 1 88 95 (Pubitemid 16232393)
33. Nagaya S., Wada H., Oka K., et al. Hemostatic abnormalities and increased vascular endothelial cell markers in patients with red cell fragmentation syndrome induced by mitomycin C. Am J Hematol: 1995; 50 4 237 243 (Pubitemid 26008876)
34. Zheng X. L., Kaufman R. M., Goodnough L. T., Sadler J. E. Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. Blood: 2004; 103 11 4043 4049 (Pubitemid 38685342)
35. McLeod B. C. Apheresis: Principles and Practice. 3rd ed. Bethesda, MD AABB Press: 2010
36. Schrijvers B. F., Flyvbjerg A., De Vriese A. S. The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int: 2004; 65 6 2003 2017 (Pubitemid 38669987)
37. Eremina V., Jefferson J. A., Kowalewska J., et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med: 2008; 358 11 1129 1136 (Pubitemid 351398487)
38. Kapiteijn E., Brand A., Kroep J., Gelderblom H. Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukoencephalopathy syndrome. Ann Oncol: 2007; 18 10 1745 1747 (Pubitemid 47506266)
39. Izzedine H., Brocheriou I., Deray G., Rixe O. Thrombotic microangiopathy and anti-VEGF agents. Nephrol Dial Transplant: 2007; 22 5 1481 1482
40. Bollée G., Patey N., Cazajous G., et al. Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib. Nephrol Dial Transplant: 2009; 24 2 682 685
41. Sugimoto H., Hamano Y., Charytan D., et al. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem: 2003; 278 15 12605 12608 (Pubitemid 36800018)
42. Scappaticci F. A., Skillings J. R., Holden S. N., et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst: 2007; 99 16 1232 1239 (Pubitemid 47299901)
43. Zhu X., Wu S., Dahut W. L., Parikh C. R. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis: 2007; 49 2 186 193 (Pubitemid 46178407)
44. Frangié C., Lefaucheur C., Medioni J., Jacquot C., Hill G. S., Nochy D. Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma. Lancet Oncol: 2007; 8 2 177 178 (Pubitemid 46158384)
45. van Heeckeren W. J., Ortiz J., Cooney M. M., Remick S. C. Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker? J Clin Oncol: 2007; 25 21 2993 2995 (Pubitemid 47218042)
46. Roncone D., Satoskar A., Nadasdy T., Monk J. P., Rovin B. H. Proteinuria in a patient receiving anti-VEGF therapy for metastatic renal cell carcinoma. Nat Clin Pract Nephrol: 2007; 3 5 287 293 (Pubitemid 46674523)
47. Gottschall J. L., Neahring B., McFarland J. G., Wu G. G., Weitekamp L. A., Aster R. H. Quinine-induced immune thrombocytopenia with hemolytic uremic syndrome: clinical and serological findings in nine patients and review of literature. Am J Hematol: 1994; 47 4 283 289 (Pubitemid 24372282)
48. Bougie D. W., Birenbaum J., Rasmussen M., Poncz M., Aster R. H. Quinine-dependent, platelet-reactive monoclonals mimic antibodies found in patients with quinine-induced immune thrombocytopenia. Blood: 2009; 113 5 1105 1111
49. Kojouri K., Vesely S. K., George J. N. Quinine-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: frequency, clinical features, and long-term outcomes. Ann Intern Med: 2001; 135 12 1047 1051 (Pubitemid 33151026)
50. Glynne P., Salama A., Chaudhry A., Swirsky D., Lightstone L. Quinine-induced immune thrombocytopenic purpura followed by hemolytic uremic syndrome. Am J Kidney Dis: 1999; 33 1 133 137 (Pubitemid 29031220)
51. Christie D. J., Weber R. W., Mullen P. C., Cook J. M., Aster R. H. Structural features of the quinidine and quinine molecules necessary for binding of drug-induced antibodies to human platelets. J Lab Clin Med: 1984; 104 5 730 740 (Pubitemid 15190084)
52. Park Y. A., Hay S. N., King K. E., et al. Is it quinine TTP/HUS or quinine TMA? ADAMTS13 levels and implications for therapy. J Clin Apher: 2009; 24 3 115 119
53. Vesely S. K., George J. N., Lämmle B., et al. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood: 2003; 102 1 60 68 (Pubitemid 36759636)